Johnson & Johnson $JNJ Shares Sold by Builder Investment Group Inc. ADV

Builder Investment Group Inc. ADV trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,836 shares of the company’s stock after selling 133 shares during the period. Johnson & Johnson makes up approximately 1.1% of Builder Investment Group Inc. ADV’s holdings, making the stock its 21st biggest holding. Builder Investment Group Inc. ADV’s holdings in Johnson & Johnson were worth $4,557,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Diversified Enterprises LLC boosted its stake in Johnson & Johnson by 4.0% in the second quarter. Diversified Enterprises LLC now owns 9,780 shares of the company’s stock valued at $1,494,000 after acquiring an additional 378 shares in the last quarter. Cahaba Wealth Management Inc. lifted its stake in shares of Johnson & Johnson by 28.2% during the second quarter. Cahaba Wealth Management Inc. now owns 6,931 shares of the company’s stock worth $1,059,000 after buying an additional 1,523 shares during the period. Eastover Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.9% during the second quarter. Eastover Investment Advisors LLC now owns 43,332 shares of the company’s stock worth $6,619,000 after buying an additional 820 shares during the period. West Branch Capital LLC lifted its stake in shares of Johnson & Johnson by 28.1% during the second quarter. West Branch Capital LLC now owns 32,530 shares of the company’s stock worth $4,969,000 after buying an additional 7,130 shares during the period. Finally, Twelve Points Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 1.4% during the second quarter. Twelve Points Wealth Management LLC now owns 13,404 shares of the company’s stock worth $2,047,000 after buying an additional 190 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.1%

Shares of NYSE JNJ opened at $179.69 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The stock has a market cap of $432.75 billion, a PE ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average of $174.41 and a 200 day moving average of $162.05.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the company earned $2.82 EPS. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Barclays lifted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Finally, The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.